Abstract:The cellular prion protein, PrP C , has been postulated to function as a receptor for α-synuclein, potentially facilitating cell-to-cell spreading and/or toxicity of α-synuclein aggregates in neurodegenerative disorders such as Parkinson's disease. Previously, we generated the "Salt (S)" and "No Salt (NS)" strains of α-synuclein aggregates that cause distinct pathological phenotypes in M83 transgenic mice overexpressing A53T-mutant human α-synuclein. To test the hypothesis that PrP C facilitates the propagation of α-synuclein aggregates, we produced M83 mice that either express or do not express PrP C . Following intracerebral inoculation with the S or NS strain, the absence of PrP C in M83 mice did not prevent disease development and had minimal influence on α-synuclein strain-specified attributes such as the extent of cerebral α-synuclein deposition, selective targeting of specific brain regions and cell types, the morphology of induced α-synuclein deposits, and the structural fingerprints of protease-resistant α-synuclein aggregates. Likewise, there were no appreciable differences in disease manifestation between PrP C -expressing and PrP C -lacking M83 mice following intraperitoneal inoculation of the S strain. Interestingly, intraperitoneal inoculation with the NS strain resulted in two distinct disease phenotypes, indicative of α-synuclein strain evolution, but this was also independent of PrP C expression. Overall, these results suggest that PrP C plays at most a minor role in the propagation, neuroinvasion, and evolution of α-synuclein strains in mice that express A53T-mutant human α-synuclein. Thus, other putative receptors or cell-to-cell propagation mechanisms may have a larger effect on the spread of α-synuclein aggregates during disease. During Parkinson's disease and related neurodegenerative disorders, the protein α-synuclein clumps together in the brain to form aggregates. α-Synuclein aggregates can spread between cells, and this process is believed to underlie disease progression. Thus, blocking the spread of α-synuclein aggregates may be a good therapeutic strategy for preventing the progression of Parkinson's disease. The details of how α-synuclein aggregates spread from cell to cell in the brain remain unclear, but it has been proposed that the cellular prion protein (PrP C ) may facilitate spreading by acting as a receptor for α-synuclein aggregates. However, this notion remains controversial. In this study, we compared the spread of α-synuclein aggregates within and to the brain in mice that either possessed or lacked PrP C . We found that the spreading of α-synuclein aggregates was largely independent of the presence of PrP C . This suggests that PrP C may not be an effective therapeutic target for attenuating the spread of α-synuclein aggregates in Parkinson's disease.

The Spreading and Effects of Human Recombinant {alpha}-Synuclein Preformed Fibrils in the Cerebrospinal Fluid of Mice

Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy

Alpha-Synuclein Pre-Formed Fibrils Injected into Prefrontal Cortex Primarily Spread to Cortical and Subcortical Structures

Virally encoded single-chain antibody fragments targeting alpha-synuclein protect against motor impairments and neuropathology in a mouse model of synucleinopathy

Alpha-synuclein inclusion responsive microglia are resistant to CSF1R inhibition

Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb

Alpha‐synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain

Deficits in basal and evoked striatal dopamine release following alpha‐synuclein preformed fibril injection: An in vivo microdialysis study

α-Synuclein aggregation decreases cortico-amygdala connectivity and impairs social behavior in mice

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease

Mechanisms of Alpha-Synuclein Seeded Aggregation in Neurons Revealed by Fluorescence Lifetime Imaging

Endogenous Alpha-Synuclein is Essential for the Transfer of Pathology by Exosome-Enriched Extracellular Vesicles, Following Inoculation with Preformed Fibrils in vivo

α-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model

Intercellular transmission of alpha-synuclein

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease

Brain Regions Susceptible to Alpha-Synuclein Spreading

Characterization of pSer129-αSyn Pathology and Neurofilament Light-Chain Release across In Vivo, Ex Vivo, and In Vitro Models of Pre-Formed-Fibril-Induced αSyn Aggregation

Evaluation of blood flow as a route for propagation in experimental synucleinopathy

Templating of Monomeric Alpha-Synuclein Induces Inflammation and SNpc Dopamine Neuron Death in a Genetic Mouse Model of Synucleinopathy.

Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease

CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice